**Genpharmasec Limited** (NSE/BSE listed) is an Indian pharmaceutical and diagnostic entity currently undergoing a high-impact strategic pivot. Formerly known as **Generic Pharmasec Limited**, the company has transitioned from its legacy in chemical manufacturing and securities trading toward a vertically integrated healthcare model. Today, the company operates at the intersection of medical diagnostic distribution, pharmaceutical manufacturing (CDMO/CRO), and clinical laboratory services. --- ### **Core Business Segments & Revenue Drivers** The company’s operations are structured into three primary reportable segments, with a clear strategic shift toward high-margin diagnostic and pharmaceutical activities. #### **1. Diagnostic Pharma Equipment (The "i-STAT" Franchise)** Genpharmasec is a specialized provider of medical diagnostic solutions, specifically targeting the intensive care segment (**ICU/ICCU**). * **Abbott Point of Care (USA) Partnership:** The company holds the distribution rights for the **i-STAT Analyser** and its cartridges across India. These hand-held blood analysers provide critical results in **10 minutes**. * **Direct Import Model:** To optimize margins, the company directly imports equipment from **Abbott POC, USA**. In FY2024-25, the company imported **110 i-STAT Analysers** and **3,59,161 cartridges** at a cost of approximately **₹11.97 Crores**. * **Specialized Infrastructure:** The company maintains a dedicated **Cold Room** facility for cartridge storage, ensuring a strict temperature range of **+2°C to +8°C**. #### **2. Pharmaceutical Distribution & Super Stockist Operations** * **Amneal Healthcare Partnership:** In **December 2024**, the company signed a **Super Stockist Agreement** with **Amneal Healthcare Private Limited (AHPL)**. AHPL has provided a minimum annual sales commitment of approximately **₹60 Crore** for the 2025 calendar year. * **Specialized Divisions:** The company holds distribution rights for **Onco** (Oncology) and **Opthal** (Ophthalmology) divisions through Amneal. #### **3. Investment & Trading in Securities** * While the company continues to engage in the secondary securities market, this segment has historically faced volatility. Management is intentionally diversifying away from this segment to focus on stable diagnostic and laboratory services. --- ### **Strategic Pivot: Manufacturing & Global Expansion** Genpharmasec is aggressively moving up the value chain from a pure trading entity to a manufacturing-led pharmaceutical company. #### **The Derren Healthcare (DHPL) Acquisition** On **July 25, 2025**, the company completed a landmark **70% stake** acquisition in **Derren Healthcare Pvt Ltd** for a total outlay of approximately **₹14.44 Crore**. * **Facility:** A **40,000 sq. ft. WHO-GMP** certified injectable unit in Gujarat. * **Capacity:** Annual capacity of **8.64 Crore vials** and **8.64 Crore ampules**. * **Utilization:** Production is currently scaling toward **90% capacity**. * **Regulatory Roadmap:** DHPL is applying for **EU** and **US FDA** approvals to enter regulated Western markets. #### **Subsidiary Footprint** | Entity | Stake | Business Focus | | :--- | :--- | :--- | | **Clinigenome India Pvt Ltd** | **99.99%** | Establishing clinical labs in **Mumbai, Kolkata, Delhi, Hyderabad, and Chennai**. | | **Genpharmasec Middle East DMCC** | **52%** | Dubai-based trading of medical equipment and food supplements; export hub for DHPL formulations. | --- ### **Financial Performance & Capital Structure** The company has demonstrated significant bottom-line growth, characterized by a sharp increase in profitability despite moderate revenue growth. #### **Standalone Financial Highlights** | Particulars (₹ in Crore) | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Revenue from Operations** | **32.96** | **30.41** | **25.52** | | **Profit Before Tax (PBT)** | **3.45** | **0.47** | **0.28** | | **Profit After Tax (PAT)** | **2.47** | **0.05** | **1.12** | #### **Solvency and Capital Raising** * **Rights Issue (Feb 2024):** Raised **₹48.45 Crore** by allotting **27,68,59,850 shares** at **₹1.75 per share**. Funds were utilized for the DHPL acquisition, debt repayment, and working capital. * **Debt Profile:** The **Debt-to-Equity Ratio** improved to **4.73%** (March 2025). Total debt stands at a modest **₹314.69 Lakhs**, primarily consisting of unsecured loans from Directors. * **Authorized Capital:** Increased to **₹56 Crore** to support expansion. * **Borrowing Limits:** Shareholders approved an increase in borrowing limits from **₹100 Crore to ₹500 Crore**. --- ### **Risk Management & Mitigation Framework** The company employs a structured framework overseen by a **Risk Management Committee** to mitigate operational and financial dependencies. #### **Operational Risk Mitigation** * **Principal Dependency:** To reduce over-reliance on **Abbott Point of Care**, the company is actively onboarding new MNC partners such as **Sphingotec Biomarkers** and **Joinstar System** (via Rivaara Labs). * **Credit Risk:** Managed via individual risk limits and historical ageing analysis. As of March 2025, **₹1,315.69 Lakhs** of the **₹2,112.82 Lakhs** in trade receivables were aged under 6 months. #### **Market & Regulatory Risks** * **Equity Price Sensitivity:** The company holds a portfolio of quoted instruments. A **+/- 5%** fluctuation in market prices impacts profit/loss by approximately **₹5.99 Lakhs** (based on March 2025 fair value of **₹1.19 Crore**). * **Labour Codes:** Following the consolidation of 29 legislations into **four New Labour Codes** (effective **Nov 2025**), the company conducted actuarial valuations and found **no material incremental impact** on gratuity obligations. * **Taxation:** The company transitioned to the **Section 115BAA** tax regime in FY 2022-23. --- ### **Governance & Shareholder Information** * **Board Composition:** 6 Directors, including **Sohan Chaturvedi** (Whole-Time Director & CFO) and 3 Independent Directors. * **Shareholding:** **99.88%** of equity shares are held in dematerialized form. * **Dividend Policy:** No dividend was recommended for the recent cycles as the company prioritizes resource conservation for the DHPL integration and laboratory expansion. * **Related Party Transactions:** The company has secured shareholder approval for material transactions up to **FY 2027-28** to facilitate seamless resource transfers within the expanded group structure.